(NASDAQ: RLYB) Rallybio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 27.58%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 41.33%.
Rallybio's earnings in 2025 is -$41,652,000.On average, 6 Wall Street analysts forecast RLYB's earnings for 2025 to be -$36,228,870, with the lowest RLYB earnings forecast at -$36,855,667, and the highest RLYB earnings forecast at -$33,784,362. On average, 6 Wall Street analysts forecast RLYB's earnings for 2026 to be -$32,008,437, with the lowest RLYB earnings forecast at -$33,291,281, and the highest RLYB earnings forecast at -$28,080,509.
In 2027, RLYB is forecast to generate -$32,392,872 in earnings, with the lowest earnings forecast at -$31,122,564 and the highest earnings forecast at -$33,345,604.